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AbstrAct
background There are many single-gene causes of 
steroid-resistant nephrotic syndrome (SRNS) and the 
list continues to grow rapidly. Prompt comprehensive 
diagnostic testing is key to realising the clinical benefits 
of a genetic diagnosis. This report describes a bespoke-
designed, targeted next-generation sequencing (NGS) 
diagnostic gene panel assay to detect variants in 37 
genes including the ability to identify copy number 
variants (CNVs).
Methods This study reports results of 302 patients 
referred for SRNS diagnostic gene panel analysis. 
Phenotype and clinical impact data were collected using 
a standard proforma. Candidate variants detected by 
NGS were confirmed by Sanger sequencing/Multiplex 
Ligation-dependent Probe Amplification with subsequent 
family segregation analysis where possible.
results Clinical presentation was nephrotic syndrome 
in 267 patients and suspected Alport syndrome (AS) in 
35. NGS panel testing determined a likely genetic cause 
of disease in 44/220 (20.0%) paediatric and 10/47 
(21.3%) adult nephrotic cases, and 17/35 (48.6%) of 
haematuria/AS patients. Of 71 patients with genetic 
disease, 32 had novel pathogenic variants without a 
previous disease association including two with deletions 
of one or more exons of NPHS1 or NPHS2.
conclusion Gene panel testing provides a genetic 
diagnosis in a significant number of patients presenting 
with SRNS or suspected AS. It should be undertaken 
at an early stage of the care pathway and include the 
ability to detect CNVs as an emerging mechanism for 
genes associated with this condition. Use of clinical 
genetic testing after diagnosis of SRNS has the potential 
to stratify patients and assist decision-making regarding 
management.
IntroductIon
Patients with nephrotic syndrome (NS) suffer a 
breakdown of the glomerular filtration barrier 
at the level of the podocyte leading to massive 
proteinuria, hypoalbuminaemia and oedema.1 The 
majority of patients display sensitivity to steroids 
(steroid-sensitive nephrotic syndrome (SSNS)). 
Patients with steroid-resistant nephrotic syndrome 
(SRNS) account for 5%–10% of cases.2 Patients 
with SRNS often need invasive renal biopsy to 
determine characteristic histological features of 
the disease such as focal segmental glomeruloscle-
rosis (FSGS), and many progress to end-stage renal 
disease within 5 years.3 4
Pathogenic variants in single genes affecting 
podocyte function are a common cause of SRNS, 
reported in up to 29.5% of a predominantly 
childhood cohort.5 There is a differing spectrum 
of disease genes and pathogenic variants associ-
ated with congenital and childhood-onset disease 
in comparison with adult disease, and genes may 
present a renal-only phenotype or NS as part of a 
wider syndrome. Alport syndrome (AS) is associated 
with pathogenic variants in COL4A3, COL4A4 or 
COL4A5 and may present with proteinuria (some 
with FSGS on biopsy), and more commonly haema-
turia.6 The renal histology is characterised by an 
alteration of the glomerular basement membrane. 
Variants in COL4A3 and COL4A4 have been iden-
tified in association with FSGS, together with thin 
basement membrane nephropathy but without the 
extrarenal features of AS.7
The proportion of single-gene cases identified 
inversely correlates with the age of onset with 
69.4%–100% of congenital-onset disease reported 
as having a genetic aetiology.5 8 Over 53 genes, both 
recessive and dominant, have been associated with 
SRNS.9 10 The phenotypic spectrum is widening, 
both in terms of age of onset11 and phenotypic 
variability, with novel phenotypes for individual 
genes emerging.12 Recent evidence suggests that 
the phenotype of a pathogenic variant in an SRNS 
gene can be modified by a variant in one of the 
collagen genes (COL4A3, COL4A4, COL4A5).13 14 
The phenotype may also depend on the location of 
the variant within the gene/protein,15 and whether 
single or multiple variants are present in one or 
more genes.16
Timely genetic testing can considerably alter 
patient management and facilitate a greater under-
standing of the genetic complexity of the condi-
tion.17 Recent studies report a multiple-gene 
testing approach using next-generation sequencing 
(NGS).5 13 18 19 Only a single NGS study has reported 
copy number variants (CNV) in NS genes,10 hence 
the contribution of this mechanism to SRNS is 
currently largely unknown, although evidence has 
suggested this as a mechanism.20 21 Several studies 
report patients with a typical phenotype and only 
a single recessive pathogenic variant.22 23 This 
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suggests there may be as yet uncharacterised variants and that a 
comprehensive NGS assay with the ability to detect CNVs would 
be of increased value.
We have developed a clinically approved gene panel test for 
37 SRNS and collagen-related genes (table 1) using a targeted 
amplicon-based NGS assay and bespoke bioinformatics analysis 
that detects both single-nucleotide variants (SNVs) and CNVs in 
batches of 12–16 patients. Importantly, the panel has the flexi-
bility to extend according to discovery of new genes. An enlarged 
panel of 70 renal-associated genes has been offered since March 
2017 for new referrals including novel genes recently reported 
associated with SRNS such as NUP93, NUP107, NUP205, 
KANK1, KANK4, MAGI2, EMP2 and ANLN.24–28
Methods
In total, 302 patients were referred with informed consent for 
diagnostic gene panel analysis over a 26-month period. The 
diagnostic test has been formally assessed for validity, and socio-
legal/ethical implications by the UK Genetic Testing Network 
and UK National Health Service (NHS) commissioners through 
the gene dossier process, and was undertaken in an accredited 
UK NHS Laboratory. Data presented pertain only to anonymised 
auditing of routine diagnostic testing; therefore, this study was 
not subject to ethical approval.
The sequencing and bioinformatics protocol is described in 
brief with further details as supplementary material. A custom 
HaloPlex Target Enrichment System (Agilent) was designed to 
target 37 genes associated with SRNS (table 1). Samples were 
sequenced on a MiSeq (Illumina) analyser following the manu-
facturer’s protocol. Bioinformatic analysis was performed using 
a bespoke pipeline based on the Broad Institutes’ Best Practice 
guidelines.29 Variants were classified according to the Associa-
tion for Clinical Genetic Science (ACGS) best practice guidelines 
(see online supplementary table 1).30 In subsequent discussion, 
Class 4 and Class 5 variants are grouped together and termed 
‘likely-pathogenic’ (LP). Class 3 are variants of unknown clinical 
significance (VUS). Class 3–5 variants were confirmed by Sanger 
sequencing.
Where possible, relative testing was undertaken using Sanger 
sequencing to determine phase (cis or trans) and segregation. 
CNVs in patients with single heterozygous variants in recessive 
genes were identified by CONTRA31 and confirmed using multi-
plex ligation-dependent probe amplification (MLPA).
Clinical data were supplied by a proforma. This included a 
question to gauge potential management changes as a result 
of the genetic analysis: ‘Will the result from this genetic test 
lead to a change in immunosuppression?’ Response to this was 
at individual clinician’s discretion and was not mandatory for 
processing of samples.
results
demographics
The majority of patients had a clinical diagnosis of idiopathic 
nephrotic syndrome, mostly SRNS, but 12 were SSNS either 
frequently-relapsing or steroid-dependent. Thirty-five patients 
were referred with features suggestive of AS including haema-
turia, a family history, hearing loss or thin basement membrane 
on biopsy. For clinical analyses, we have therefore separated 
the cohort into SRNS, SSNS and Alport groups. Referrals were 
received from 12 different countries (see online supplemen-
tary figure 1). The timing of disease onset was known for 196 
patients: 32 (16.3 %) were congenital (<3 months), 16 (8.2%) 
infantile (3–12 months), 101 (51.5%) childhood (1–12 years), 
17 (8.7%) juvenile (13–18 years) and 30 (15.3%) adult (>18 
years). Of 255 patients with SRNS, a biopsy report was available 
in 133 which showed FSGS in 109 (82.0%) and minimal change 
disease (MCD) in 8 (6.0%). In 9 of 12 patients with SSNS with 
a biopsy report, 3 (33.3%) had FSGS and 3 (33.3%) had MCD. 
In patients with SRNS, 35 (23.8%) of 147 with data available 
had a family history of renal disease. Among 132 patients with 
SRNS where data on age of onset and family history were avail-
able, 52.6% (10/19) of adults compared with 12.4% (14/113) 
of patients<18 years had a positive family history. This may 
represent differing referral patterns in clinicians caring for adult 
patients with NS such that they were less likely to request genetic 
testing for adults without a family history. Among 35 patients in 
the Alport group, 78.6% of 28 patients with data had a family 
history of a similar disease. Other demographic data are shown 
in table 2.
data quality and gene panel performance
An average gene coverage of 99.26% coding sequence at 
a minimum read depth of 30× was achieved on a typical 
12-patient run. The per-gene coverage is shown in table 1. 
The ACGS reporting time guideline for large panel tests is 112 
calendar days.32 The median time from receipt of samples to 
issue of a report was 74 days (IQR 49–106 days). With clinically 
urgent referrals, it was possible to reduce substantially the turn-
around time with complete genetic panel reports provided for 
17 patients within 4 weeks and the fastest positive case report 
(NPHS2 compound heterozygote) being issued in 22 calendar 
days.
Genetic variants
Targeted gene panel testing of all 302 patients identified 71 
(23.5%) with a likely genetic cause for disease. The genetic diag-
nostic rate among the group with SRNS was 21.2%, including 
44/209 (21.1%) paediatric and 10/46 (21.7%) adult nephrotic 
cases (figure 1). In patients with SRNS where family history was 
known, the genetic diagnostic rate was 11/35 (31.4%) in those 
with a positive family history and 30/112 (26.8%) in those with 
negative family history. In patients with SRNS where family 
history was known and with age of onset over 18 years, the 
genetic diagnostic rate was 2/10 (20.0%) in those with a posi-
tive family history and 3/9 (33.3%) in those with negative family 
history. The rate in those with parental consanguinity was 5/13 
(38.5%) compared with 28/104 (26.9%) in those without. In all 
the 12 patients with SSNS, no pathogenic variants were found 
in any of the 37 genes tested. The genetic diagnostic rate was 
48.6% for the Alport group.
The spectrum of pathogenic variants is summarised in table 3. 
Detailed phenotypic and variant data for the 71 patients with 
genetic disease is shown in online supplementary table 2.
The most frequently detected LP variants in the SRNS group 
(n=255) were in NPHS1, WT1 and NPHS2 in 12 (4.7%), 11 
(4.3%) and 7 (2.7%) patients, respectively. In the Alport group, 
the variants were all in collagen genes: COL4A3, COL4A4 
and COL4A5 in 5 (14.3%), 2 (5.7%) and 10 (28.6%) patients, 
respectively. Of note, five SRNS/FSGS patients had LP vari-
ants in COL4A3, COL4A4 and COL4A5 (one, one and three 
patients, respectively) including a single novel LP COL4A3 
variant, c.698G>A, p.(Gly233Glu), in a patient with a domi-
nant family history of FSGS (patient 4) which tracked with 
disease in an affected brother. Among patients with SRNS/
FSGS who were found to have genetic disease (excluding those 
with collagen variants), there was an autosomal-dominant 
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mode of inheritance in 16/41 (36.6%) of those with disease 
onset  ≤18  years  compared  with  6/7  (85.7%)  of  those  >18 
years.
Variants of unknown significance
In addition to the patients with LP variants, a further 40 patients 
had one or more VUS (see online supplementary table 3). Among 
the 52 VUS in these patients, the most frequently involved 
genes were: 28.9% in collagen genes; 7.7% each in NPHS1 and 
NPHS2; and 5.8% each in INF2, MYH9, PLCE1 and PTPRO. 
Of the 71 patients with likely genetic disease, 11 cases had 12 
additional VUS in genes other than the main causative one for 
that patient, most frequently collagen genes in 41.7% and WT1 
in 16.7%. Overall, of the 64 recorded VUS, 31.3% were in 
collagen genes, 6.3% in NPHS2, 6.3% in NPHS1 and 6.3% in 
MYH9.
novel variants
Among the 71 patients with a genetic cause for disease, 32 had 
variants without a previous disease association including 26 with 
one or more novel variants absent from population databases. 
Two patients had gene deletions of one or more exons detected 
by CNV analysis (figure 2). Patient 44 (see online supplementary 
table 2) presented with congenital nephrotic syndrome (CNS) 
and had a maternally inherited truncating deletion of NPHS1 
exons 23–29 together with a paternally inherited previously-re-
ported nonsense variant c.866G>A p.(Trp289*).33 Patient 55 
also presented with CNS and genetic testing revealed a mater-
nally inherited frame shift deletion of NPHS2 exon 2 in combi-
nation with a paternally inherited c.1032delT variant. The 
c.1032delT variant has been previously reported as the most 
frequent pathogenic variant in NPHS2 in Poland (Kashubian 
region).23 Both parents of patient 55 are of Polish extraction. In 
addition to these two patients, a further 30 had variants without 
a previous disease association in the following genes: ACTN4 (1 
patient), COL4A3 (2), COL4A4 (1), COL4A5 (10), INF2 (2), 
LAMB2 (2), NPHS1 (5), NPHS2 (2), SMARCAL1 (1), TRPC6 (1) 
and WT1 (3).
Novel INF2 LP variants were detected in two adult-onset NS 
patients: p.(Tyr50Asp) (patient 25) and p.(Leu165Arg) (patient 
26). Both were missense variants affecting highly conserved 
residues within the diaphanous inhibitory domain of the INF2 
protein consistent with the previously reported spectrum of 
disease-causing variants. Segregation supports pathogenicity, 
p.(Tyr50Asp) co-segregating with disease in five affected family 
members and p.(Leu165Arg) present in one affected family 
member and absent in two unaffected family members. An addi-
tional sensory neuropathy phenotype previously reported in 
12.5% of INF2 cases34 was also seen in affected family members 
with the p.(Tyr50Asp) variant.
Two novel missense WT1 variants were identified in the known 
hotspot region (exons 6–9)35 in patients with atypical presenta-
tion and no recorded extrarenal manifestations. p.(His339Arg) 
in exon 7 (patient 61) co-segregates with disease in six affected 
family members with a variable phenotype ranging from child-
hood-onset nephrotic-range proteinuria to mild proteinuria 
presenting in adulthood. The p.(Arg390Gln) variant in WT1 
exon 8 (patient 65) was associated with age of onset of 30 years 
and was inherited from an affected father who was diagnosed 
in his 30s. Although WT1 is normally associated with child-
hood-onset disease, these findings are consistent with a previ-
ously described biphasic childhood and adulthood presentation 
of variants in WT1.5G
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single heterozygous variants in recessive NPHS1 and NPHS2
In six clinically affected SRNS cases (patients 112–117 in 
online supplementary table 4), full coding sequence analysis 
detected a single heterozygous pathogenic variant in NPHS1 or 
NPHS2 that has been previously published as disease causing. No 
CNVs were identified. The finding of these variants may be inci-
dental. However, given the low incidence of SRNS, the young 
age of onset (<5 years, two with CNS) and the low frequency/
absence of the variants in databases of subjects without known 
renal disease it is possible that there are additional NPHS1/
NPHS2 variants in unsequenced intronic or promoter regions 
which may act in combination to cause the phenotype in these 
patients. These findings were reported as compatible with the 
phenotype but insufficient to make a diagnosis.
Three of these patients (112, 113 and 114) with early-onset 
SRNS were heterozygous for previously reported rare pathogenic 
variants in NPHS1. Patient 112 developed SRNS under the age 
of 4 years with a heterozygous p.(Asp105Asn) variant previously 
reported in a Japanese patient with CNS where a second variant 
was not detected.36Patient 113 had a heterozygous p.(Arg299Cys) 
variant. Patient 114, from a Jordanian consanguineous family, 
who presented with CNS and FSGS on biopsy had a c.1138C>T, 
p.(Gln380*) nonsense variant but, in common with the other cases, 
no other likely pathogenic variants in NPHS1 or other genes in the 
panel. Patient 117 had a single heterozygous missense variant in 
NPHS2: c.872G>A, p.(Arg291Gln) previously reported as patho-
genic in the homozygous/compound heterozygous state. Patient 
117 also had a novel single heterozygous variant in NPHS1: 
c.2512C>A, p.(Pro838Thr) which is not reported in population 
databases and prediction tools suggest is deleterious.
Two further patients (115 and 116) presenting with classical 
NS had single previously reported pathogenic variants in NPHS2 
p.(Arg138Gln) (exon 3) and p.(Leu156Phefs*11) (exon 4) in a 
compound heterozygous state with the NPHS2 non-neutral poly-
morphism p.(Arg229Gln). Tory et al15 previously demonstrated 
that p.(Arg229Gln) is only pathogenic in combination with vari-
ants in exons 7 or 8 and therefore should not be pathogenic 
with p.(Arg138Gln) or p.(Leu156Phefs*11).15 It is possible that 
a third intronic or promoter variant in NPHS2 is contributing to 
these patients’ phenotypes.
table 2 Clinical characteristics of cohort
total cohort
steroid-resistant nephrotic 
syndrome
steroid-sensitive nephrotic 
syndrome
haematuria/ Alport 
syndrome
Total patients 302 255 12 35
Male (%) 165 (54.6) 138 (54.1) 10 (83.3) 17 (48.6)
Age at onset/testing*in years (%)
  0–0.25 32 (10.6) 31 (12.2) 1 (8.3) 0 (0)
  0.25–1 16 (5.3) 13 (5.1) 0 (0) 3 (8.6)
  1–12 147 (48.7) 125 (49.0) 9 (75) 13 (37.1)
  13–18 45 (14.9) 40 (15.7) 1 (8.3) 4 (11.4)
  >18 62 (20.5) 46 (18.0) 1 (8.3) 15 (42.9)
Family history positive/number with data available (%) 58/183 (31.7) 35/147 (23.8) 1/8 (12.5) 22/28 (78.6)
Consanguinity/number with data available (%) 17/141 (12.1) 13/117 (11.1) 3/9 (33.3) 1/15 (6.7)
Ethnicity (% of patients where data available)
  White 99 (65.8) 83 (66.4) 3 (37.5) 13 (76.5)
  Indian 14 (9.4) 12 (9.6) 2 (25) 0 (0)
  Black African/Caribbean 7 (4.7) 5 (4.0) 1 (12.5) 1 (5.9)
  Pakistani 6 (4.0) 3 (2.4) 2 (25) 1 (5.9)
  Bangladeshi 2 (1.3) 2 (1.6) 0 (0) 0 (0)
  Asian 2 (1.3) 2 (1.6) 0 (0) 0 (0)
  Middle Eastern 2 (1.3) 2 (1.6) 0 (0) 0 (0)
  Arabic 2 (1.3) 2 (1.6) 0 (0) 0 (0)
  Mixed 3 (2.0) 3 (2.4) 0 (0) 0 (0)
  Other 13 (8.7) 11 (8.8) 0 (0) 2 (11.8)
  No ethnicity data available 152 130 4 18
Biopsy findings (% of patients where data available); 
number (%) with genetic diagnosis
  FSGS 115 (71.9); 27 (23.5) 109 (82.0); 26 (23.9) 3 (33.3); 0 (0) 3 (16.7); 1 (33.3)
  MCD 11 (6.9); 0 (0) 8 (6.0); 0 (0) 3 (33.3); 0 (0) 0 (0)
  Mesangioproliferative GN 3 (1.9); 0 (0) 3 (2.3); 0 (0) 0 (0) 0 (0)
  DMS 5 (3.1); 2 (40.0) 4 (3.0); 2 (50.0) 1 (11.1); 0 (0) 0 (0)
  Finnish type 2 (1.3); 2 (100) 2 (1.5); 2 (100) 0 (0) 0 (0)
  Alport 8 (5.0); 7 (87.5) 0 (0) 0 (0) 8 (44.4); 7 (87.5)
  TBMN 4 (2.5); 1 (25.0) 0 (0) 0 (0) 4 (22.2); 1 (25.0)
  Other 12 (7.5); 3 (25.0) 7 (5.3); 3 (42.9) 2 (22.2); 0 (0) 3 (16.7); 0 (0)
  No biopsy data available/not biopsied 142 122 3 17
Total with likely pathogenic variants (%) 71 (23.5) 54 (21.2) 0 (0) 17 (48.6)
*For patients where no data were available for age at disease onset, the age at genetic testing was used.
DMS, diffuse mesangial sclerosis; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; MCD, minimal change disease; TBMN, thin basement membrane 
nephropathy.
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Figure 1 Flow chart of patients by phenotype at presentation, age and genetic diagnosis. ‘Age’ refers to age at diagnosis or, if not available, age at 
genetic testing. ‘Genetic’ refers to the number of cases with likely pathogenic variants. SRNS, steroid-resistant nephrotic syndrome; SSNS, steroid-sensitive 
nephrotic syndrome.
table 3 Genes with likely pathogenic variants in the steroid-resistant nephrotic syndrome group and haematuria/Alport syndrome group
Gene with likely pathogenic 
variant steroid-resistant nephrotic syndrome (number of patients) haematuria/Alport syndrome (number of patients)
Age group* ≤18 years (n=209) >18 years (n=46) total (n=255) ≤18 years (n=20) >18 years (n=15) total (n=35)
NPHS1 12 0 12 0 0 0
WT1 9 2 11 0 0 0
NPHS2 7 0 7 0 0 0
LMX1B 4 0 4 0 0 0
INF2 0 3 3 0 0 0
LAMB2 3 0 3 0 0 0
MYH9 2 0 2 0 0 0
PLCE1 2 0 2 0 0 0
ACTN4 1 0 1 0 0 0
SCARB2 0 1 1 0 0 0
SMARCAL1 1 0 1 0 0 0
TRPC6 0 1 1 0 0 0
COL4A3 0 1 1 3 2 5
COL4A4 1 1† 2 0 2 2
COL4A5 2 1 3 5 5 10
Total 44 10 54  8 9 17
*For patients where no data were available for age at disease onset, the age at genetic testing was used. None of the 12 patients with steroid-sensitive nephrotic syndrome had 
likely pathogenic variants and so are not shown in this table.
†This patient was referred with hypertensive nephrosclerosis and a family history of renal disease.
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likely pathogenic variants by age of disease onset
The age of disease onset was known with certainty for 164 
(64.3%) of 255 patients referred with a clinical presentation of 
SRNS and online supplementary figure 2 illustrates the genetic 
diagnostic rates by age group. In patients with CNS, the diag-
nostic rate was 58.1% (18/31) with LP variants in the following 
genes: NPHS1 (12 patients), LAMB2 (3 patients), NPHS2 (2 
patients) and WT1 (1 patient). For cases of SRNS with known 
age of onset >18 years, the rate was 28.6% (6/21) with LP vari-
ants in INF2 (two patients), WT1 (two patients), SCARB2 (one 
patient) and TRPC6 (one patient).
clinical impact of genetic testing
Physicians were asked whether the results of genetic testing 
would alter immunosuppressive management in patients with 
SRNS. Responses were obtained in relation to 71 (27.8%) of 
these patients. The response rate was not high enough to make 
definitive conclusions, but broadly clinicians reported that results 
would influence decisions to reduce or stop immunosuppression 
and one physician indicated that treatment decisions would be 
made after the gene panel results were known. The diagnostic 
test result from 67 patients resulted in the subsequent testing of 
148 family members including two prenatal tests for LAMB2 and 
NPHS2 pathogenic variants. At least nine family tests are known 
to have helped inform suitability for donor transplant treat-
ment. Other familial testing has provided diagnoses for relatives 
and aided in clarifying variant pathogenicity. Other responses 
confirmed that genetic testing impacts on diagnosis and prog-
nosis after transplant.
dIscussIon
Gene panel testing is becoming more and more relevant for 
screening rare diseases, with greatly improved cost/benefit. The 
knowledge of the genetic basis of SRNS has expanded consid-
erably over the past five years with several national and inter-
national cohorts recently published5 10 37 where genetic analysis 
was undertaken either as part of a research study or on a limited 
number of genes dependent on the country or institution where 
the patient was seen. This study reports on large gene panel 
testing available on a clinical diagnostic basis within the NHS 
in the UK. Analysis is performed at a single accredited centre, 
with technological and bioinformatics expertise developed over 
Figure 2 NPHS1 and NPHS2 copy number variants. (A) NPHS1 deletion of exons 23–29. (B) NPHS2 deletion of exon 2. Next-generation sequencing (NGS) 
read depth analysis (top) with results confirmed by MLPA (below). NGS fold change in copy number (Log2 ratio) is shown across the locus (Open Reading 
Frame (ORF) scale) and averaged for each exon (exon scale). MLPA shows patient peaks in dark grey and normal control peaks in light grey. The patient/
normal ratios are shown with deletions having ratio <0.75.
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several years in collaboration with academic research institutes. 
Although the majority of referrals are received from UK clini-
cians, 41% of referrals are from outside the UK.
The frequency of likely pathogenic variants among patients 
with SRNS was 21.2%. This is marginally lower than 24%–34% 
reported in other studies which included predominantly subjects 
with childhood-onset disease.5 8 19 37 The cohort reported here 
includes patients referred for genetic testing by clinicians in routine 
practice and is therefore more heterogeneous than those included in 
international registries of SRNS. The cohort was also not restricted 
to patients with childhood-onset disease with 30 patients having 
known onset in adulthood. As illustrated in online supplementary 
figure 2, the genetic diagnostic rate decreased with increasing age 
of onset from congenital to childhood, similar to that reported in 
another international cohort.5 However, there was an increased 
diagnostic rate in the juvenile and adult subgroups. It is likely that 
the adults referred by clinicians for gene panel testing are a filtered 
population of cases as suggested by the higher frequency of a posi-
tive family history of 52.6%.
Twelve patients with SSNS were referred for genetic testing 
and none had a potentially pathogenic variant. Thus far, no 
purely monogenic causes for SSNS have been identified.38 Associ-
ations between SSNS and variants in EMP2, KANK1 and KANK2 
have been described in family studies but evaluation in larger 
cohorts did not identify additional patients with pathogenic vari-
ants.25 27KANK2 was included in the gene panel reported here 
and no likely pathogenic variants were identified. The updated 
version of the panel includes EMP2, KANK1 and KANK4. Our 
current recommendation for clinicians is not to use the NGS 
gene panel test for patients with persistently SSNS unless there 
are specific reasons to suspect a genetic aetiology.
In this study, 100% of LP variants identified by NGS meeting 
diagnostic variant-calling quality parameters have subsequently 
been confirmed as being present on Sanger sequencing. Sanger 
confirmation of NGS LP variants is currently in line with best 
practice ACGS guidance. It also provides a confirmation of sample 
identity following pooling of samples during the NGS process 
and establishes a familial test for relatives. As further evidence is 
collected, confirmatory testing may become redundant.
The use of gene panel testing supersedes stepwise screening 
protocols8 and avoids phenotype selection bias, allowing detec-
tion of pathogenic variants in genes that would not necessarily 
be expected from the clinical presentation such as the two adult 
cases with a WT1 variant without any manifesting extrarenal 
features. In addition, variants in secondary genes which may 
potentially contribute to the phenotype of the patient can be 
identified by a panel approach.
Gene panel screening identified 32 likely pathogenic vari-
ants without a previous disease association. Absence or rarity 
in population data is used as evidence to support pathogenicity; 
however, it is acknowledged that some ethnicities in this global 
cohort were either not known or may currently be insufficiently 
represented in population databases. Where possible, segre-
gation analysis was performed to provide additional evidence 
to support pathogenicity; however, family members were not 
always available for testing, reflecting the use of this panel in a 
clinical setting.
The interpretation of variants of unknown significance in 
a global cohort is also a challenge of panel testing. As well as 
segregation analysis, future expansion of population databases 
will allow improved filtering of population-specific variants and 
functional work may also aid the interpretation of variants.
This study has demonstrated two cases of CNVs present in NS 
genes; therefore, CNV analysis of NGS data should be routinely 
undertaken as part of the variant analysis pipeline, together with 
confirmation using a second method such as MLPA. It is also 
apparent that there are a number of clinically typical cases with only 
a single known NPHS1 or NPHS2 pathogenic variant detected, 
suggesting deep intronic or regulatory variants if these genes are 
truly recessive in mechanism. Future whole-genome sequencing in 
these patients may help to elucidate a genetic pathogenesis.
The timing of testing in relation to disease onset and the speed 
of genetic reporting are important for clinical utility. It is poten-
tially possible to generate results within 1–2 weeks, thereby 
avoiding diagnostic biopsy in some cases. In certain contexts, 
earlier testing and more rapid turnaround are important because 
results may have direct consequences for prenatal testing and 
patient treatment. Pathogenic variants in COQ2, COQ6 or 
PDSS2, coding for proteins the coenzyme Q10 pathway, may 
indicate the potential for benefit from treatment with this 
enzyme.39 40 Identification of a causative variant may lead to 
clinicians stopping or avoiding intensification of immuno-
suppressive treatment. There has, however, been a report of a 
patient with NS, diffuse mesangial sclerosis and PLCE1 variants 
who responded to treatment with steroids and ciclosporin.41 
Cases of unaffected older children and adults with the same 
homozygous PLCE1 variants as their affected relatives suggest 
a more complex genotype–phenotype interplay and raise the 
possibility of spontaneous improvement rather than a true 
response to medication.42 43 Some patients with WT1 variants 
have responded to steroids and immunosuppression.44 Certain 
pathogenic variants, such as in WT1, should prompt search 
for other features of an associated syndrome, such as Frasier 
syndrome and risk of gonadoblastoma.45
The presence of a causative variant in SRNS is associated with 
a lower risk of post-transplantation recurrence of disease, occur-
ring in 25.8% of patients testing negative for genetic disease 
compared with 4.5% of those with an identified variant in a 
European cohort37 and 0% in a published UK cohort.10 Avail-
ability of results supporting a genetic diagnosis may prompt more 
rapid progression to potentially definitive treatment with trans-
plantation rather than persisting with partially effective medical 
therapies. Targeted sequencing of family members resulting from 
gene panel testing has been used prior to transplantation, partic-
ularly in cases with autosomal-dominant gene variants.
We report that NGS gene panel testing with bioinformatics 
analysis for SNVs and CNVs at an early stage after diagnosis 
of SRNS or suspected AS with results in a clinically relevant 
time scale has the potential to improve patient stratification and 
the care pathway.
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